Impact of Bone-Modifying Agents on Post-Bone Metastasis Survival Across Cancer Types

Impact of Bone-Modifying Agents on Post-Bone Metastasis Survival Across Cancer Types

Background: Bone metastasis is associated with a poor prognosis. Bone-modifying agents (BMA) are commonly used for the prevention or treatment of skeletal-related events (SRE) in patients with bone metastasis; however, whether or not treatment with BMA improves survival remains unclear. In this stud...

Full description

Saved in:
Bibliographic Details
Main Authors: Hironari Tamiya, Kazumi Nishino, Yuji Kato, Reina Nakahashi-Kato, Yurika Kosuga-Tsujimoto, Shota Kinoshita, Rie Suzuki, Makiyo Watanabe, Toru Wakamatsu, Shigeki Kakunaga, Satoshi Takenaka
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Current Oncology
Subjects:
bone-modifying agent
bone metastasis
survival
cancer
treatment
Online Access:https://www.mdpi.com/1718-7729/32/1/42
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items